Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans (Q35987384)

11 August 2017

Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans (English)

1 reference

11 August 2017

Ng-Mak DS

1

1 reference

11 August 2017

Hu XH

2

1 reference

11 August 2017

Chen Y

3

1 reference

11 August 2017

Ma L

4

1 reference

11 August 2017

Solomon G

5

1 reference

11 August 2017

language of work or name

1 reference

30 May 2007

1 reference

International Journal of Clinical Practice

11 August 2017

1 reference

11 August 2017

61

1 reference

11 August 2017

7

1 reference

11 August 2017

1091-1111

1 reference

Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Acute drug treatment of migraine attack

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Real-world experiences in migraine therapy with rizatriptan

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Migraine: diagnosis and management.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Comparison of rizatriptan and other triptans on stringent measures of efficacy

2 October 2017

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2007.01400.X

A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17537184

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Guidelines for controlled trials of drugs in migraine: second edition

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17537184

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1742-1241.2007.01400.X

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

17537184

1 reference